Raras
Buscar doenças, sintomas, genes...
Esclerose lateral amiotrófica
ORPHA:803CID-10 · G12.2CID-11 · 8B60.0PCDT · SUSDOENÇA RARA

A esclerose lateral amiotrófica (ELA) é uma doença neurológica que piora com o tempo. Ela se caracteriza por uma fraqueza e paralisia progressiva dos músculos, que acontece porque os neurônios motores — as células nervosas que controlam os movimentos — morrem ou ficam enfraquecidos. Isso ocorre em partes do cérebro que controlam os movimentos, nas vias nervosas que ligam o cérebro à medula, no tronco cerebral e na medula espinhal.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A esclerose lateral amiotrófica (ELA) é uma doença neurológica que piora com o tempo. Ela se caracteriza por uma fraqueza e paralisia progressiva dos músculos, que acontece porque os neurônios motores — as células nervosas que controlam os movimentos — morrem ou ficam enfraquecidos. Isso ocorre em partes do cérebro que controlam os movimentos, nas vias nervosas que ligam o cérebro à medula, no tronco cerebral e na medula espinhal.

Pesquisas ativas
38 ensaios
974 total registrados no ClinicalTrials.gov
Publicações científicas
36.013 artigos
Último publicado: 2026 Mar 20
Medicamentos
4 registrados
TOFERSEN, RILUZOLE, MECASERMIN

Tem tratamento?

4 medicamentos registrados
Ver detalhes, fases e interações →
TOFERSENRILUZOLEMECASERMINQUINIDINE

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
5.2
Europe
Início
Adult
🏥
SUS: Cobertura parcialScore: 65%
PCDT disponível2 medicamentos CEAFCID-10: G12.2
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
55 sintomas
💪
Músculos
47 sintomas
🦴
Ossos e articulações
6 sintomas
🫁
Pulmão
5 sintomas
📏
Crescimento
4 sintomas
👁️
Olhos
4 sintomas

+ 115 sintomas em outras categorias

Características mais comuns

100%prev.
Esclerose lateral amiotrófica
90%prev.
Neurodegeneração
Muito frequente (99-80%)
90%prev.
Fraqueza muscular generalizada
Muito frequente (99-80%)
90%prev.
Atrofia do neurônio motor
Muito frequente (99-80%)
55%prev.
Fraqueza fatigável dos músculos bulbares
Frequente (79-30%)
55%prev.
Atrofia do músculo esquelético
Frequente (79-30%)
245sintomas
Muito frequente (4)
Frequente (32)
Ocasional (10)
Muito raro (1)
Sem dados (198)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 245 características clínicas mais associadas, ordenadas por frequência.

Esclerose lateral amiotróficaAmyotrophic lateral sclerosis
Muito frequente100%
NeurodegeneraçãoNeurodegeneration
Muito frequente (99-80%)90%
Fraqueza muscular generalizadaGeneralized muscle weakness
Muito frequente (99-80%)90%
Atrofia do neurônio motorMotor neuron atrophy
Muito frequente (99-80%)90%
Fraqueza fatigável dos músculos bulbaresFatigable weakness of bulbar muscles
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico36.013PubMed
Últimos 10 anos200publicações
Pico2026198 papers
Linha do tempo
2026Hoje · 2026🧪 1982Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

46 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant, Autosomal recessive, Not applicable.

TREM2Triggering receptor expressed on myeloid cells 2Major susceptibility factor inTolerante
FUNÇÃO

Forms a receptor signaling complex with TYROBP which mediates signaling and cell activation following ligand binding (PubMed:10799849). Acts as a receptor for amyloid-beta protein 42, a cleavage product of the amyloid-beta precursor protein APP, and mediates its uptake and degradation by microglia (PubMed:27477018, PubMed:29518356). Binding to amyloid-beta 42 mediates microglial activation, proliferation, migration, apoptosis and expression of pro-inflammatory cytokines, such as IL6R and CCL3, a

LOCALIZAÇÃO

Cell membraneSecreted

VIAS BIOLÓGICAS (4)
DAP12 signalingDAP12 interactionsOther semaphorin interactionsImmunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
MECANISMO DE DOENÇA

Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2

An autosomal recessive disease characterized by presenile frontal dementia with leukoencephalopathy and basal ganglia calcification. In most cases the disorder first manifests in early adulthood as pain and swelling in ankles and feet, followed by bone fractures. Neurologic symptoms manifest in the fourth decade of life as a frontal lobe syndrome with loss of judgment, euphoria, and disinhibition. Progressive decline in other cognitive domains begins to develop at about the same time. The disorder culminates in a profound dementia and death by age 50 years.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
47.7 TPM
Substância negra
20.1 TPM
Pulmão
17.4 TPM
Nervo tibial
14.5 TPM
Hipotálamo
10.7 TPM
OUTRAS DOENÇAS (8)
polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2amyotrophic lateral sclerosisprogressive non-fluent aphasiabehavioral variant of frontotemporal dementia
HGNC:17761UniProt:Q9NZC2
LRP12Low-density lipoprotein receptor-related protein 12Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Probable receptor, which may be involved in the internalization of lipophilic molecules and/or signal transduction. May act as a tumor suppressor

LOCALIZAÇÃO

MembraneMembrane, coated pit

VIAS BIOLÓGICAS (1)
Retinoid metabolism and transport
MECANISMO DE DOENÇA

Oculopharyngodistal myopathy 1

A form of oculopharyngodistal myopathy, a muscle disorder characterized by progressive ptosis, external ophthalmoplegia, and weakness of the masseter, facial, pharyngeal, and distal limb muscles. The myopathological features are presence of rimmed vacuoles in the muscle fibers and myopathic changes of differing severity. OPDM1 inheritance pattern is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
21.3 TPM
Útero
17.0 TPM
Artéria tibial
10.5 TPM
Fallopian Tube
10.3 TPM
Aorta
9.5 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (3)
oculopharyngodistal myopathy 1amyotrophic lateral sclerosis 28oculopharyngodistal myopathy
HGNC:31708UniProt:Q9Y561
ALS2AlsinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May act as a GTPase regulator. Controls survival and growth of spinal motoneurons (By similarity)

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
RAC1 GTPase cycleRAB GEFs exchange GTP for GDP on RABs
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 2

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

OUTRAS DOENÇAS (4)
infantile-onset ascending hereditary spastic paralysisjuvenile primary lateral sclerosisamyotrophic lateral sclerosis type 2, juvenilejuvenile amyotrophic lateral sclerosis
HGNC:443UniProt:Q96Q42
TIA1Cytotoxic granule associated RNA binding protein TIA1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

RNA-binding protein involved in the regulation of alternative pre-RNA splicing and mRNA translation by binding to uridine-rich (U-rich) RNA sequences (PubMed:11106748, PubMed:12486009, PubMed:17488725, PubMed:8576255). Binds to U-rich sequences immediately downstream from a 5' splice sites in a uridine-rich small nuclear ribonucleoprotein (U snRNP)-dependent fashion, thereby modulating alternative pre-RNA splicing (PubMed:11106748, PubMed:8576255). Preferably binds to the U-rich IAS1 sequence in

LOCALIZAÇÃO

NucleusCytoplasmCytoplasm, Stress granule

VIAS BIOLÓGICAS (1)
FGFR2 alternative splicing
MECANISMO DE DOENÇA

Welander distal myopathy

An autosomal dominant disorder characterized by adult onset of distal muscle weakness predominantly affecting the distal long extensors of the hands, with slow progression to involve all small hand muscles and the lower legs. Skeletal muscle biopsy shows myopathic changes and prominent rimmed vacuoles. Rare homozygous patients showed earlier onset, faster progression, and proximal muscle involvement.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
112.7 TPM
Cervix Endocervix
105.2 TPM
Útero
102.6 TPM
Cervix Ectocervix
100.3 TPM
Fallopian Tube
98.5 TPM
OUTRAS DOENÇAS (2)
distal myopathy, Welander typeamyotrophic lateral sclerosis 26 with or without frontotemporal dementia
HGNC:11802UniProt:P31483
SPG11SpatacsinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May play a role in neurite plasticity by maintaining cytoskeleton stability and regulating synaptic vesicle transport

LOCALIZAÇÃO

Cytoplasm, cytosolNucleusCell projection, axonCell projection, dendrite

MECANISMO DE DOENÇA

Spastic paraplegia 11, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
33.0 TPM
Tireoide
29.3 TPM
Baço
26.6 TPM
Fibroblastos
23.3 TPM
Pulmão
22.7 TPM
OUTRAS DOENÇAS (4)
amyotrophic lateral sclerosis type 5Charcot-Marie-Tooth disease axonal type 2Xhereditary spastic paraplegia 11juvenile amyotrophic lateral sclerosis
HGNC:11226UniProt:Q96JI7
SPTLC1Serine palmitoyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the serine palmitoyltransferase multisubunit enzyme (SPT) that catalyzes the initial and rate-limiting step in sphingolipid biosynthesis by condensing L-serine and activated acyl-CoA (most commonly palmitoyl-CoA) to form long-chain bases. The SPT complex is also composed of SPTLC2 or SPTLC3 and SPTSSA or SPTSSB. Within this complex, the heterodimer with SPTLC2 or SPTLC3 forms the catalytic core (PubMed:19416851, PubMed:33558762, PubMed:36170811). The composition of the serine palmit

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Sphingolipid de novo biosynthesis
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 27, juvenile

A form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. ALS27 is an autosomal dominant form manifesting as toe walking and gait abnormalities in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
55.6 TPM
Esôfago - Mucosa
37.6 TPM
Cervix Ectocervix
36.9 TPM
Ovário
36.8 TPM
Vagina
36.5 TPM
OUTRAS DOENÇAS (4)
neuropathy, hereditary sensory and autonomic, type 1Aamyotrophic lateral sclerosis 27, juvenilejuvenile amyotrophic lateral sclerosishereditary sensory and autonomic neuropathy type 1
HGNC:11277UniProt:O15269
TUBA4ATubulin alpha-4A chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin

LOCALIZAÇÃO

Cytoplasm, cytoskeleton

VIAS BIOLÓGICAS (10)
HCMV Early EventsPKR-mediated signalingGap junction assemblyAggrephagyAssembly and cell surface presentation of NMDA receptors
MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 9

An autosomal dominant neurodegenerative disorder characterized by adult onset of frontotemporal dementia or amyotrophic lateral sclerosis with upper and lower neuron involvement. Some patients manifest both frontotemporal dementia and amyotrophic lateral sclerosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
239.9 TPM
Músculo esquelético
203.5 TPM
Skin Sun Exposed Lower leg
202.8 TPM
Skin Not Sun Exposed Suprapubic
197.3 TPM
Brain Frontal Cortex BA9
175.9 TPM
OUTRAS DOENÇAS (1)
amyotrophic lateral sclerosis type 22
HGNC:HGNC:12407UniProt:P68366
SETXHelicase senataxinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

ATP-dependent 5'->3' DNA/RNA helicase that preferentially unwinds RNA substrates over DNA, playing a crucial role in resolving R-loops and promoting transcription termination (PubMed:36864660). Plays a role in transcription regulation by its ability to modulate RNA Polymerase II (Pol II) binding to chromatin and through its interaction with proteins involved in transcription (PubMed:19515850, PubMed:21700224). Contributes to the mRNA splicing efficiency and splice site selection (PubMed:19515850

LOCALIZAÇÃO

NucleusNucleus, nucleoplasmNucleus, nucleolusCytoplasmChromosomeChromosome, telomereCell projection, axonCell projection, growth cone

MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAN2 is an autosomal recessive form associated with peripheral neuropathy and elevated serum alpha-fetoprotein, immunoglobulins and, less commonly, creatine kinase levels. Some SCAN2 patients manifest oculomotor apraxia.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
50.4 TPM
Linfócitos
39.4 TPM
Tireoide
36.1 TPM
Baço
32.8 TPM
Pulmão
25.9 TPM
OUTRAS DOENÇAS (2)
spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2amyotrophic lateral sclerosis type 4
HGNC:445UniProt:Q7Z333
CYLDUbiquitin carboxyl-terminal hydrolase CYLDDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Deubiquitinase that specifically cleaves 'Lys-63'- and linear 'Met-1'-linked polyubiquitin chains and is involved in NF-kappa-B activation and TNF-induced necroptosis (PubMed:18313383, PubMed:18636086, PubMed:26670046, PubMed:26997266, PubMed:27458237, PubMed:27591049, PubMed:27746020, PubMed:29291351, PubMed:32185393). Negatively regulates NF-kappa-B activation by deubiquitinating upstream signaling factors (PubMed:12917689, PubMed:12917691, PubMed:32185393). Contributes to the regulation of ce

LOCALIZAÇÃO

CytoplasmCytoplasm, perinuclear regionCytoplasm, cytoskeletonCell membraneCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, spindleCytoplasm, cytoskeleton, cilium basal body

VIAS BIOLÓGICAS (6)
NOD1/2 Signaling PathwayUb-specific processing proteasesNegative regulators of DDX58/IFIH1 signalingTNFR1-induced proapoptotic signalingTNFR1-induced NF-kappa-B signaling pathway
MECANISMO DE DOENÇA

Cylindromatosis, familial

A disorder characterized by multiple skin tumors that develop from skin appendages, such as hair follicles and sweat glands. Affected individuals typically develop large numbers of tumors called cylindromas that arise predominantly in hairy parts of the body with approximately 90% on the head and neck. In severely affected individuals, cylindromas may combine into a confluent mass which may ulcerate or become infected (turban tumor syndrome). Individuals with familial cylindromatosis occasionally develop other types of tumors including spiradenomas that begin in sweat glands, and trichoepitheliomas arising from hair follicles.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
45.5 TPM
Artéria tibial
26.4 TPM
Baço
25.6 TPM
Aorta
24.3 TPM
Pituitária
22.6 TPM
OUTRAS DOENÇAS (5)
trichoepithelioma, multiple familial, 1frontotemporal dementia and/or amyotrophic lateral sclerosis 8familial cylindromatosisBrooke-Spiegler syndrome
HGNC:2584UniProt:Q9NQC7
SIGMAR1Sigma non-opioid intracellular receptor 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. Involved in the regulation of different receptors it plays a role in BDNF signaling and EGF signaling. Also regulates ion channels like the potassium channel and could modulate neurotransmitter release. Plays a role in calcium signaling through modulation together with ANK2 of the ITP3R-depend

LOCALIZAÇÃO

Nucleus inner membraneNucleus outer membraneNucleus envelopeCytoplasmic vesicleEndoplasmic reticulum membraneMembraneLipid dropletCell junctionCell membraneCell projection, growth conePostsynaptic density membrane

VIAS BIOLÓGICAS (1)
Potential therapeutics for SARS
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 16, juvenile

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
143.9 TPM
Fígado
106.6 TPM
Cervix Ectocervix
101.1 TPM
Cervix Endocervix
93.5 TPM
Útero
86.8 TPM
OUTRAS DOENÇAS (3)
amyotrophic lateral sclerosis type 16autosomal recessive distal spinal muscular atrophy 2juvenile amyotrophic lateral sclerosis
HGNC:8157UniProt:Q99720
C9orf72Guanine nucleotide exchange factor C9orf72Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a guanine-nucleotide releasing factor (GEF) for Rab GTPases by promoting the conversion of inactive RAB-GDP to the active form RAB-GTP (PubMed:27103069, PubMed:27193190, PubMed:27617292, PubMed:28195531, PubMed:37821429). Acts as a GEF for RAB39A which enables HOPS-mediated autophagosome-lysosome membrane tethering and fusion in mammalian autophagy (PubMed:37821429). Component of the C9orf72-SMCR8 complex where both subunits display GEF activity and that regulates autophagy (PubMed:27103

LOCALIZAÇÃO

CytoplasmNucleusCytoplasm, P-bodyCytoplasm, Stress granuleEndosomeLysosomeCytoplasmic vesicle, autophagosomeAutolysosomeSecretedCell projection, axonCell projection, growth conePerikaryonCell projection, dendritePresynapsePostsynapseNucleus membrane

MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 1

An autosomal dominant neurodegenerative disorder characterized by adult onset of frontotemporal dementia and/or amyotrophic lateral sclerosis in an affected individual. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis.

OUTRAS DOENÇAS (1)
frontotemporal dementia and/or amyotrophic lateral sclerosis 1
HGNC:HGNC:28337UniProt:Q96LT7
GLE1mRNA export factor GLE1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for the export of mRNAs containing poly(A) tails from the nucleus into the cytoplasm. May be involved in the terminal step of the mRNA transport through the nuclear pore complex (NPC)

LOCALIZAÇÃO

NucleusCytoplasmNucleus, nuclear pore complex

VIAS BIOLÓGICAS (1)
Transport of Mature mRNA derived from an Intron-Containing Transcript
MECANISMO DE DOENÇA

Lethal congenital contracture syndrome 1

A form of lethal congenital contracture syndrome, an autosomal recessive disorder characterized by degeneration of anterior horn neurons, extreme skeletal muscle atrophy, and congenital non-progressive joint contractures (arthrogryposis). The contractures can involve the upper or lower limbs and/or the vertebral column, leading to various degrees of flexion or extension limitations evident at birth. LCCS1 patients manifest early fetal hydrops and akinesia, micrognathia, pulmonary hypoplasia, pterygia, and multiple joint contractures. It leads to prenatal death.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
66.4 TPM
Linfócitos
52.3 TPM
Cérebro - Hemisfério cerebelar
35.0 TPM
Fibroblastos
31.7 TPM
Cerebelo
30.4 TPM
OUTRAS DOENÇAS (3)
lethal congenital contracture syndrome 1lethal arthrogryposis-anterior horn cell disease syndromeamyotrophic lateral sclerosis
HGNC:4315UniProt:Q53GS7
ERBB4Receptor tyrosine-protein kinase erbB-4Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially

LOCALIZAÇÃO

Cell membraneNucleusMitochondrion

VIAS BIOLÓGICAS (6)
Signaling by ERBB4Nuclear signaling by ERBB4Downregulation of ERBB4 signalingSignaling by ERBB2Signaling by ERBB2 TMD/JMD mutants
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 19

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
9.1 TPM
Aorta
8.6 TPM
Brain Anterior cingulate cortex BA24
8.6 TPM
Brain Frontal Cortex BA9
8.0 TPM
Brain Caudate basal ganglia
7.6 TPM
OUTRAS DOENÇAS (3)
amyotrophic lateral sclerosis type 19amyotrophic lateral sclerosisautosomal dominant non-syndromic intellectual disability
HGNC:3432UniProt:Q15303
FIG4Polyphosphoinositide phosphataseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Dual specificity phosphatase component of the PI(3,5)P2 regulatory complex which regulates both the synthesis and turnover of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2) (PubMed:17556371, PubMed:33098764). Catalyzes the dephosphorylation of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2) to form phosphatidylinositol 3-phosphate (PubMed:33098764). Has serine-protein phosphatase activity acting on PIKfyve to stimulate its lipid kinase activity, its catalytically activity being requ

LOCALIZAÇÃO

Endosome membrane

VIAS BIOLÓGICAS (1)
Synthesis of PIPs at the Golgi membrane
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 4J

A recessive demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
25.0 TPM
Brain Frontal Cortex BA9
22.9 TPM
Aorta
22.2 TPM
Baço
20.8 TPM
Pituitária
20.7 TPM
OUTRAS DOENÇAS (5)
amyotrophic lateral sclerosis type 11Charcot-Marie-Tooth disease type 4Jbilateral parasagittal parieto-occipital polymicrogyriaYunis-Varon syndrome
HGNC:16873UniProt:Q92562
PRPHPeripherin-2Major susceptibility factor inTolerante
FUNÇÃO

Essential for retina photoreceptor outer segment disk morphogenesis, may also play a role with ROM1 in the maintenance of outer segment disk structure (By similarity). Required for the maintenance of retinal outer nuclear layer thickness (By similarity). Required for the correct development and organization of the photoreceptor inner segment (By similarity)

LOCALIZAÇÃO

MembraneCell projection, cilium, photoreceptor outer segmentPhotoreceptor inner segment

MECANISMO DE DOENÇA

Retinitis pigmentosa 7

A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.

EXPRESSÃO TECIDUAL(Tecido-específico)
Testículo
46.2 TPM
Cólon sigmoide
25.3 TPM
Cólon transverso
11.4 TPM
Cervix Ectocervix
6.4 TPM
Esôfago - Muscular
6.0 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (2)
amyotrophic lateral sclerosisamyotrophic lateral sclerosis type 1
HGNC:9461UniProt:P23942
CCNFCyclin-FDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:20596027, PubMed:22632967, PubMed:26818844, PubMed:27080313, PubMed:27653696, PubMed:28852778). The SCF(CCNF) E3 ubiquitin-protein ligase complex is an integral component of the ubiquitin proteasome system (UPS) and links proteasome degradation to the cell cycle (PubMed:20596027, PubMed:26818844,

LOCALIZAÇÃO

NucleusCytoplasm, perinuclear regionCytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole

VIAS BIOLÓGICAS (2)
Antigen processing: Ubiquitination & Proteasome degradationNeddylation
MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 5

A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. FTDALS5 is an autosomal dominant form with age-dependent penetrance. Penetrance is estimated to be 50% by age 56 and 100% by age 61.

OUTRAS DOENÇAS (2)
frontotemporal dementia and/or amyotrophic lateral sclerosis 5amyotrophic lateral sclerosis
HGNC:1591UniProt:P41002
VAPBVesicle-associated membrane protein-associated protein B/CDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Endoplasmic reticulum (ER)-anchored protein that mediates the formation of contact sites between the ER and endosomes via interaction with FFAT motif-containing proteins such as STARD3 or WDR44 (PubMed:32344433, PubMed:33124732). Interacts with STARD3 in a FFAT motif phosphorylation dependent manner (PubMed:33124732). Via interaction with WDR44 participates in neosynthesized protein export (PubMed:32344433). Participates in the endoplasmic reticulum unfolded protein response (UPR) by inducing ER

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Sphingolipid de novo biosynthesisRHOG GTPase cycleRAC2 GTPase cycleRHOC GTPase cycleRHOA GTPase cycle
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 8

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
36.1 TPM
Brain Spinal cord cervical c-1
36.1 TPM
Tireoide
30.7 TPM
Brain Frontal Cortex BA9
28.9 TPM
Artéria tibial
26.7 TPM
OUTRAS DOENÇAS (3)
adult-onset proximal spinal muscular atrophy, autosomal dominantamyotrophic lateral sclerosis type 8amyotrophic lateral sclerosis
HGNC:12649UniProt:O95292
ATXN2Ataxin-2Major susceptibility factor inAltamente restrito
FUNÇÃO

Involved in EGFR trafficking, acting as negative regulator of endocytic EGFR internalization at the plasma membrane

LOCALIZAÇÃO

Cytoplasm

MECANISMO DE DOENÇA

Spinocerebellar ataxia 2

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to cerebellum degeneration with variable involvement of the brainstem and spinal cord. SCA2 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I) which are characterized by cerebellar ataxia in combination with additional clinical features like optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy and dementia. SCA2 is characterized by hyporeflexia, myoclonus and action tremor and dopamine-responsive parkinsonism. In some patients, SCA2 presents as pure familial parkinsonism without cerebellar signs.

OUTRAS DOENÇAS (3)
spinocerebellar ataxia type 2amyotrophic lateral sclerosislate-onset Parkinson disease
HGNC:10555UniProt:Q99700
TAF15Transcription initiation factor TFIID subunit 12Candidate gene tested inAltamente restrito
FUNÇÃO

The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 an

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (9)
Regulation of TP53 Activity through PhosphorylationRNA Polymerase II Promoter EscapeRNA Polymerase II HIV Promoter EscapeRNA Polymerase II Pre-transcription EventsHIV Transcription Initiation
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
199.6 TPM
Testículo
191.9 TPM
Fibroblastos
180.0 TPM
Esôfago - Muscular
141.2 TPM
Útero
137.9 TPM
OUTRAS DOENÇAS (2)
extraskeletal myxoid chondrosarcomaamyotrophic lateral sclerosis
HGNC:11547UniProt:Q16514
OPTNOptineurinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays an important role in the maintenance of the Golgi complex, in membrane trafficking, in exocytosis, through its interaction with myosin VI and Rab8 (PubMed:27534431). Links myosin VI to the Golgi complex and plays an important role in Golgi ribbon formation (PubMed:27534431). Plays a role in the activation of innate immune response during viral infection. Mechanistically, recruits TBK1 at the Golgi apparatus, promoting its trans-phosphorylation after RLR or TLR3 stimulation (PubMed:27538435

LOCALIZAÇÃO

Cytoplasm, perinuclear regionGolgi apparatusGolgi apparatus, trans-Golgi networkCytoplasmic vesicle, autophagosomeCytoplasmic vesicleRecycling endosome

VIAS BIOLÓGICAS (8)
PINK1-PRKN Mediated MitophagyActivation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 TNFR1-induced proapoptotic signalingRegulation of TNFR1 signaling
MECANISMO DE DOENÇA

Glaucoma 1, open angle, E

A form of primary open angle glaucoma (POAG). POAG is characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
367.0 TPM
Artéria tibial
110.7 TPM
Ovário
99.9 TPM
Testículo
99.0 TPM
Tecido adiposo
91.4 TPM
OUTRAS DOENÇAS (4)
OPTN-related open angle glaucomaamyotrophic lateral sclerosis type 12amyotrophic lateral sclerosisglaucoma, normal tension, susceptibility to
HGNC:17142UniProt:Q96CV9
PPARGC1APeroxisome proliferator-activated receptor gamma coactivator 1-alphaModifying germline mutation inAltamente restrito
FUNÇÃO

Transcriptional coactivator for steroid receptors and nuclear receptors (PubMed:10713165, PubMed:20005308, PubMed:21376232, PubMed:28363985, PubMed:32433991). Greatly increases the transcriptional activity of PPARG and thyroid hormone receptor on the uncoupling protein promoter (PubMed:10713165, PubMed:20005308, PubMed:21376232). Can regulate key mitochondrial genes that contribute to the program of adaptive thermogenesis (PubMed:10713165, PubMed:20005308, PubMed:21376232). Plays an essential ro

LOCALIZAÇÃO

NucleusNucleus, PML bodyCytoplasm

VIAS BIOLÓGICAS (10)
Expression of BMAL (ARNTL), CLOCK, and NPAS2Heme signalingTranscriptional activation of mitochondrial biogenesisRORA,B,C and NR1D1 (REV-ERBA) regulate gene expressionRegulation of RUNX2 expression and activity
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
17.3 TPM
Coração - Átrio
13.5 TPM
Rim - Medula
12.6 TPM
Músculo esquelético
11.0 TPM
Glândula salivar
10.8 TPM
OUTRAS DOENÇAS (1)
amyotrophic lateral sclerosis
HGNC:9237UniProt:Q9UBK2
CHCHD10Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in the maintenance of mitochondrial organization and mitochondrial cristae structure

LOCALIZAÇÃO

Mitochondrion intermembrane space

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 2

A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis.

OUTRAS DOENÇAS (5)
lower motor neuron syndrome with late-adult onsetfrontotemporal dementia and/or amyotrophic lateral sclerosis 2autosomal dominant mitochondrial myopathy with exercise intoleranceamyotrophic lateral sclerosis
HGNC:15559UniProt:Q8WYQ3
UBQLN2Ubiquilin-2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Plays an important role in the regulation of different protein degradation mechanisms and pathways including ubiquitin-proteasome system (UPS), autophagy and the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Mediates the proteasomal targeting of misfolded or accumulated proteins for degradation by binding (via UBA domain) to their polyubiquitin chains and by interacting (via ubiquitin-like domain) with the subunits of the proteasome (PubMed:10983987). Plays a role in the E

LOCALIZAÇÃO

CytoplasmNucleusMembraneCytoplasmic vesicle, autophagosome

VIAS BIOLÓGICAS (1)
Cargo recognition for clathrin-mediated endocytosis
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. Patients with ALS15 may develop frontotemporal dementia.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
75.5 TPM
Brain Frontal Cortex BA9
52.5 TPM
Cerebelo
48.0 TPM
Brain Nucleus accumbens basal ganglia
42.9 TPM
Fibroblastos
38.5 TPM
OUTRAS DOENÇAS (2)
amyotrophic lateral sclerosis type 15amyotrophic lateral sclerosis
HGNC:12509UniProt:Q9UHD9
GLT8D1Glycosyltransferase 8 domain-containing protein 1Major susceptibility factor inTolerante
FUNÇÃO

In vitro, catalyzes the transfer of a galactose residue from UDP-galactose onto GalNAc and GlcNAc structures

LOCALIZAÇÃO

Golgi apparatus membrane

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
92.2 TPM
Pituitária
87.6 TPM
Testículo
80.6 TPM
Tireoide
75.7 TPM
Nervo tibial
71.0 TPM
OUTRAS DOENÇAS (1)
amyotrophic lateral sclerosis
HGNC:24870UniProt:Q68CQ7
SOD1Superoxide dismutase [Cu-Zn]Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Destroys radicals which are normally produced within the cells and which are toxic to biological systems (PubMed:24140062). Catalyzes the oxidation of hydrogen sulfide (H2S) to sulfate, playing an important role in detoxifying H2S and limiting the accumulation of reactive sulfur species (RSS) such as persulfides and polysulfides (PubMed:36630448)

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (2)
Detoxification of Reactive Oxygen SpeciesPlatelet degranulation
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 1

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
378.5 TPM
Glândula adrenal
377.5 TPM
Brain Frontal Cortex BA9
347.6 TPM
Hipotálamo
301.1 TPM
Brain Spinal cord cervical c-1
289.0 TPM
OUTRAS DOENÇAS (3)
spastic tetraplegia and axial hypotonia, progressiveamyotrophic lateral sclerosis type 1amyotrophic lateral sclerosis
HGNC:11179UniProt:P00441
C9ORF72Guanine nucleotide exchange factor C9orf72Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a guanine-nucleotide releasing factor (GEF) for Rab GTPases by promoting the conversion of inactive RAB-GDP to the active form RAB-GTP (PubMed:27103069, PubMed:27193190, PubMed:27617292, PubMed:28195531, PubMed:37821429). Acts as a GEF for RAB39A which enables HOPS-mediated autophagosome-lysosome membrane tethering and fusion in mammalian autophagy (PubMed:37821429). Component of the C9orf72-SMCR8 complex where both subunits display GEF activity and that regulates autophagy (PubMed:27103

LOCALIZAÇÃO

CytoplasmNucleusCytoplasm, P-bodyCytoplasm, Stress granuleEndosomeLysosomeCytoplasmic vesicle, autophagosomeAutolysosomeSecretedCell projection, axonCell projection, growth conePerikaryonCell projection, dendritePresynapsePostsynapseNucleus membrane

MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 1

An autosomal dominant neurodegenerative disorder characterized by adult onset of frontotemporal dementia and/or amyotrophic lateral sclerosis in an affected individual. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis.

HGNC:28337UniProt:Q96LT7
TBK1Serine/threonine-protein kinase TBK1Major susceptibility factor inAltamente restrito
FUNÇÃO

Serine/threonine kinase that plays an essential role in regulating inflammatory responses to foreign agents (PubMed:10581243, PubMed:11839743, PubMed:12692549, PubMed:12702806, PubMed:14703513, PubMed:15367631, PubMed:15485837, PubMed:18583960, PubMed:21138416, PubMed:23453971, PubMed:23453972, PubMed:23746807, PubMed:25636800, PubMed:26611359, PubMed:32404352, PubMed:34363755, PubMed:32298923). Following activation of toll-like receptors by viral or bacterial components, associates with TRAF3 a

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (10)
PINK1-PRKN Mediated MitophagyDDX58/IFIH1-mediated induction of interferon-alpha/betaSARS-CoV-2 activates/modulates innate and adaptive immune responsesTRAF3-dependent IRF activation pathwayTRAF6 mediated IRF7 activation
MECANISMO DE DOENÇA

Glaucoma 1, open angle, P

A form of primary open angle glaucoma (POAG). POAG is characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. GLC1P is characterized by early onset, thin central corneas and low intraocular pressure.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
50.3 TPM
Testículo
42.8 TPM
Fibroblastos
35.0 TPM
Pulmão
30.8 TPM
Útero
30.3 TPM
OUTRAS DOENÇAS (6)
autoinflammation with arthritis and vasculitisfrontotemporal dementia and/or amyotrophic lateral sclerosis 4amyotrophic lateral sclerosisfrontotemporal dementia with motor neuron disease
HGNC:11584UniProt:Q9UHD2
SQSTM1Sequestosome-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Molecular adapter required for selective macroautophagy (aggrephagy) by acting as a bridge between polyubiquitinated proteins and autophagosomes (PubMed:15340068, PubMed:15953362, PubMed:16286508, PubMed:17580304, PubMed:20168092, PubMed:22017874, PubMed:22622177, PubMed:24128730, PubMed:28404643, PubMed:29343546, PubMed:29507397, PubMed:31857589, PubMed:33509017, PubMed:34471133, PubMed:34893540, PubMed:35831301, PubMed:37306101, PubMed:37802024). Promotes the recruitment of ubiquitinated cargo

LOCALIZAÇÃO

Cytoplasmic vesicle, autophagosomePreautophagosomal structureCytoplasm, cytosolNucleus, PML bodyLate endosomeLysosomeNucleusEndoplasmic reticulumCytoplasm, myofibril, sarcomere

VIAS BIOLÓGICAS (9)
PINK1-PRKN Mediated MitophagyPexophagyNF-kB is activated and signals survivalp75NTR recruits signalling complexesInterleukin-1 signaling
MECANISMO DE DOENÇA

Paget disease of bone 3

A disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal adult lamellar bone.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
155.2 TPM
Artéria tibial
140.4 TPM
Aorta
135.6 TPM
Fibroblastos
134.0 TPM
Glândula adrenal
131.3 TPM
OUTRAS DOENÇAS (8)
Paget disease of bone 3myopathy, distal, with rimmed vacuolesneurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onsetfrontotemporal dementia and/or amyotrophic lateral sclerosis 3
HGNC:11280UniProt:Q13501
DAODiamine oxidase [copper-containing]Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the oxidative deamination of primary amines to the corresponding aldehydes with the concomitant production of hydrogen peroxide and ammonia (PubMed:12072962, PubMed:19764817, PubMed:239684, PubMed:8144586). Its preferred substrates are the diamines histamine and 1-methylhistamine and it could therefore play a role in allergic and immune responses (PubMed:12072962). Has a broad specificity for diamines and can also act on cadaverine and putrescine, two products of amino acid catabolism

LOCALIZAÇÃO

Secreted, extracellular spaceCell membrane

VIAS BIOLÓGICAS (2)
Glyoxylate metabolism and glycine degradationPeroxisomal protein import
EXPRESSÃO TECIDUAL(Tecido-específico)
Cerebelo
40.1 TPM
Cérebro - Hemisfério cerebelar
26.7 TPM
Fígado
23.7 TPM
Brain Spinal cord cervical c-1
15.7 TPM
Substância negra
5.9 TPM
OUTRAS DOENÇAS (1)
amyotrophic lateral sclerosis
HGNC:2671UniProt:P19801
ANGAngiogeninDisease-causing germline mutation(s) inDesconhecido
FUNÇÃO

Secreted ribonuclease that can either promote or restrict cell proliferation of target cells, depending on the context (PubMed:12051708, PubMed:1400510, PubMed:19332886, PubMed:20129916, PubMed:21855800, PubMed:23047679, PubMed:23843625, PubMed:2424496, PubMed:2459697, PubMed:2730651, PubMed:27518564, PubMed:28176817, PubMed:29100074, PubMed:29748193, PubMed:3122207, PubMed:32510170, PubMed:38718836, PubMed:8159680, PubMed:8570639, PubMed:8622921, PubMed:9578571). Endocytosed in target cells via

LOCALIZAÇÃO

SecretedNucleusNucleus, nucleolusCytoplasm, Stress granule

VIAS BIOLÓGICAS (1)
tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 9

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

OUTRAS DOENÇAS (2)
amyotrophic lateral sclerosis type 9amyotrophic lateral sclerosis
HGNC:483UniProt:P03950
TARDBPTAR DNA-binding protein 43Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

RNA-binding protein that is involved in various steps of RNA biogenesis and processing (PubMed:23519609). Preferentially binds, via its two RNA recognition motifs RRM1 and RRM2, to GU-repeats on RNA molecules predominantly localized within long introns and in the 3'UTR of mRNAs (PubMed:23519609, PubMed:24240615, PubMed:24464995). In turn, regulates the splicing of many non-coding and protein-coding RNAs including proteins involved in neuronal survival, as well as mRNAs that encode proteins relev

LOCALIZAÇÃO

NucleusCytoplasmCytoplasm, Stress granuleMitochondrion

MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 10

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
121.2 TPM
Cérebro - Hemisfério cerebelar
114.9 TPM
Útero
114.8 TPM
Ovário
111.4 TPM
Tireoide
105.5 TPM
OUTRAS DOENÇAS (3)
amyotrophic lateral sclerosis type 10amyotrophic lateral sclerosisfrontotemporal dementia with motor neuron disease
HGNC:11571UniProt:Q13148
PON2Serum paraoxonase/arylesterase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Capable of hydrolyzing lactones and a number of aromatic carboxylic acid esters. Has antioxidant activity. Is not associated with high density lipoprotein. Prevents LDL lipid peroxidation, reverses the oxidation of mildly oxidized LDL, and inhibits the ability of MM-LDL to induce monocyte chemotaxis

LOCALIZAÇÃO

Membrane

VIAS BIOLÓGICAS (1)
Synthesis of 5-eicosatetraenoic acids
EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
151.8 TPM
Brain Caudate basal ganglia
141.5 TPM
Brain Nucleus accumbens basal ganglia
132.8 TPM
Glândula adrenal
123.5 TPM
Cérebro - Amígdala
113.8 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (1)
amyotrophic lateral sclerosis
HGNC:9205UniProt:Q15165
NEFHNeurofilament heavy polypeptideMajor susceptibility factor inTolerante
FUNÇÃO

Neurofilaments usually contain three intermediate filament proteins: NEFL, NEFM, and NEFH which are involved in the maintenance of neuronal caliber. NEFH has an important function in mature axons that is not subserved by the two smaller NF proteins. May additionally cooperate with the neuronal intermediate filament proteins PRPH and INA to form neuronal filamentous networks (By similarity)

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCell projection, axon

MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Próstata
158.9 TPM
Brain Frontal Cortex BA9
104.3 TPM
Córtex cerebral
67.0 TPM
Hipotálamo
63.3 TPM
Substância negra
56.2 TPM
OUTRAS DOENÇAS (3)
Charcot-Marie-Tooth disease axonal type 2CCamyotrophic lateral sclerosisamyotrophic lateral sclerosis type 1
HGNC:7737UniProt:P12036
ANXA11Annexin A11Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Binds specifically to calcyclin in a calcium-dependent manner (By similarity). Required for midbody formation and completion of the terminal phase of cytokinesis

LOCALIZAÇÃO

CytoplasmMelanosomeNucleus envelopeNucleus, nucleoplasmCytoplasm, cytoskeleton, spindle

MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 23

A form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. ALS23 is an autosomal dominant form with incomplete penetrance.

INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (3)
inclusion body myopathy and brain white matter abnormalitiesamyotrophic lateral sclerosis type 23amyotrophic lateral sclerosis
HGNC:535UniProt:P50995
PON3Serum paraoxonase/lactonase 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Has low activity towards the organophosphate paraxon and aromatic carboxylic acid esters. Rapidly hydrolyzes lactones such as statin prodrugs (e.g. lovastatin). Hydrolyzes aromatic lactones and 5- or 6-member ring lactones with aliphatic substituents but not simple lactones or those with polar substituents

LOCALIZAÇÃO

Secreted, extracellular space

VIAS BIOLÓGICAS (1)
Synthesis of 5-eicosatetraenoic acids
EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
120.6 TPM
Pituitária
41.2 TPM
Ovário
28.1 TPM
Testículo
18.8 TPM
Pulmão
11.3 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (1)
amyotrophic lateral sclerosis
HGNC:9206UniProt:Q15166
MATR3Matrin-3Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

May play a role in transcription or may interact with other nuclear matrix proteins to form the internal fibrogranular network. In association with the SFPQ-NONO heteromer may play a role in nuclear retention of defective RNAs. Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway (PubMed:2871272

LOCALIZAÇÃO

Nucleus matrix

MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 21

A neurodegenerative disorder affecting upper and lower motor neurons, resulting in muscle weakness and respiratory failure. Some patients may develop myopathic features or dementia.

OUTRAS DOENÇAS (3)
amyotrophic lateral sclerosis type 21distal myopathy with vocal cord weaknessamyotrophic lateral sclerosis
HGNC:6912UniProt:P43243
DCTN1Dynactin subunit 1Candidate gene tested inAltamente restrito
FUNÇÃO

Part of the dynactin complex that activates the molecular motor dynein for ultra-processive transport along microtubules (By similarity). Plays a key role in dynein-mediated retrograde transport of vesicles and organelles along microtubules by recruiting and tethering dynein to microtubules. Binds to both dynein and microtubules providing a link between specific cargos, microtubules and dynein. Essential for targeting dynein to microtubule plus ends, recruiting dynein to membranous cargos and en

LOCALIZAÇÃO

CytoplasmCytoplasm, cytoskeletonCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, microtubule organizing center, centrosome, centrioleCytoplasm, cytoskeleton, spindleNucleus envelopeCytoplasm, cell cortex

VIAS BIOLÓGICAS (5)
COPI-mediated anterograde transportHSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligandMHC class II antigen presentationCOPI-independent Golgi-to-ER retrograde trafficXBP1(S) activates chaperone genes
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 14

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
212.6 TPM
Cerebelo
206.3 TPM
Brain Frontal Cortex BA9
173.9 TPM
Córtex cerebral
156.5 TPM
Pituitária
134.3 TPM
OUTRAS DOENÇAS (5)
neuronopathy, distal hereditary motor, type 7BPerry syndromeamyotrophic lateral sclerosisdistal hereditary motor neuropathy type 7
HGNC:2711UniProt:Q14203
PON1Serum paraoxonase/arylesterase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation

LOCALIZAÇÃO

Secreted, extracellular space

VIAS BIOLÓGICAS (1)
Synthesis of 5-eicosatetraenoic acids
MECANISMO DE DOENÇA

Microvascular complications of diabetes 5

Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
137.4 TPM
Glândula adrenal
3.7 TPM
Pituitária
2.0 TPM
Ovário
1.7 TPM
Testículo
1.0 TPM
OUTRAS DOENÇAS (1)
amyotrophic lateral sclerosis
HGNC:9204UniProt:P27169
NEK1Serine/threonine-protein kinase Nek1Major susceptibility factor inTolerante
FUNÇÃO

Phosphorylates serines and threonines, but also appears to possess tyrosine kinase activity (PubMed:20230784). Involved in DNA damage checkpoint control and for proper DNA damage repair (PubMed:20230784). In response to injury that includes DNA damage, NEK1 phosphorylates VDAC1 to limit mitochondrial cell death (PubMed:20230784). May be implicated in the control of meiosis (By similarity). Involved in cilium assembly (PubMed:21211617)

LOCALIZAÇÃO

NucleusCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm

VIAS BIOLÓGICAS (1)
Regulation of pyruvate metabolism
MECANISMO DE DOENÇA

Short-rib thoracic dysplasia 6 with or without polydactyly

A form of short-rib thoracic dysplasia, a group of autosomal recessive ciliopathies that are characterized by a constricted thoracic cage, short ribs, shortened tubular bones, and a 'trident' appearance of the acetabular roof. Polydactyly is variably present. Non-skeletal involvement can include cleft lip/palate as well as anomalies of major organs such as the brain, eye, heart, kidneys, liver, pancreas, intestines, and genitalia. Some forms of the disease are lethal in the neonatal period due to respiratory insufficiency secondary to a severely restricted thoracic cage, whereas others are compatible with life. Disease spectrum encompasses Ellis-van Creveld syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer-Saldino syndrome, and short rib-polydactyly syndrome.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
63.9 TPM
Testículo
14.3 TPM
Cerebelo
13.0 TPM
Cérebro - Hemisfério cerebelar
13.0 TPM
Ovário
12.2 TPM
OUTRAS DOENÇAS (5)
orofaciodigital syndrome type IIshort-rib thoracic dysplasia 6 with or without polydactylyamyotrophic lateral sclerosisshort rib-polydactyly syndrome, Majewski type
HGNC:7744UniProt:Q96PY6
PFN1Profilin-1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Binds to actin and affects the structure of the cytoskeleton. At high concentrations, profilin prevents the polymerization of actin, whereas it enhances it at low concentrations. By binding to PIP2, it inhibits the formation of IP3 and DG. Inhibits androgen receptor (AR) and HTT aggregation and binding of G-actin is essential for its inhibition of AR

LOCALIZAÇÃO

Cytoplasm, cytoskeleton

VIAS BIOLÓGICAS (4)
RHO GTPases Activate ForminsSignaling by ROBO receptorsPCP/CE pathwayPlatelet degranulation
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 18

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
1612.4 TPM
Sangue
955.5 TPM
Fibroblastos
924.7 TPM
Cólon sigmoide
777.0 TPM
Aorta
763.4 TPM
OUTRAS DOENÇAS (2)
amyotrophic lateral sclerosis type 18amyotrophic lateral sclerosis
HGNC:8881UniProt:P07737
HNRNPA1Heterogeneous nuclear ribonucleoprotein A1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Involved in the packaging of pre-mRNA into hnRNP particles, transport of poly(A) mRNA from the nucleus to the cytoplasm and modulation of splice site selection (PubMed:17371836). Plays a role in the splicing of pyruvate kinase PKM by binding repressively to sequences flanking PKM exon 9, inhibiting exon 9 inclusion and resulting in exon 10 inclusion and production of the PKM M2 isoform (PubMed:20010808). Binds to the IRES and thereby inhibits the translation of the apoptosis protease activating

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (5)
FGFR2 alternative splicingmRNA Splicing - Major PathwaymRNA PolyadenylationProcessing of Capped Intron-Containing Pre-mRNADengue Virus-Host Interactions
MECANISMO DE DOENÇA

Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 3

An autosomal dominant disease characterized by disabling muscle weakness clinically resembling to limb girdle muscular dystrophy, osteolytic bone lesions consistent with Paget disease, and premature frontotemporal dementia. Clinical features show incomplete penetrance.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
1092.5 TPM
Linfócitos
728.9 TPM
Cervix Ectocervix
629.5 TPM
Cervix Endocervix
629.4 TPM
Útero
591.7 TPM
OUTRAS DOENÇAS (5)
inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 3amyotrophic lateral sclerosis type 20Finnish upper limb-onset distal myopathyamyotrophic lateral sclerosis
HGNC:5031UniProt:P09651
CFAP410Cilia- and flagella-associated protein 410Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a role in cilia formation and/or maintenance (By similarity). Plays a role in the regulation of cell morphology and cytoskeletal organization (PubMed:21834987). Involved in DNA damage repair (PubMed:26290490)

LOCALIZAÇÃO

MitochondrionCytoplasm, cytoskeleton, cilium basal bodyCell projection, cilium, photoreceptor outer segmentCytoplasm

MECANISMO DE DOENÇA

Retinal dystrophy with or without macular staphyloma

An ocular disorder characterized by decreased vision which worsen over time, and dystrophic changes in the retina, such as retinal pigment epithelium mottling and vessel narrowing. Macular staphyloma, without high myopia, is present in some patients.

INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (4)
axial spondylometaphyseal dysplasiaretinal dystrophy with or without macular staphylomaamyotrophic lateral sclerosiscone-rod dystrophy
HGNC:1260UniProt:O43822
CHMP2BCharged multivesicular body protein 2bDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The M

LOCALIZAÇÃO

Cytoplasm, cytosolLate endosome membrane

VIAS BIOLÓGICAS (1)
Late endosomal microautophagy
MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 7

A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia (FTD) is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis (ALS) is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. FTDALS7 is an autosomal dominant form characterized by onset of ALS or FTD in adulthood. A few patients may have both phenotypes.

OUTRAS DOENÇAS (5)
frontotemporal dementia and/or amyotrophic lateral sclerosis 7semantic dementiaprogressive non-fluent aphasiaamyotrophic lateral sclerosis
HGNC:24537UniProt:Q9UQN3
VCPTransitional endoplasmic reticulum ATPaseDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Necessary for the fragmentation of Golgi stacks during mitosis and for their reassembly after mitosis. Involved in the formation of the transitional endoplasmic reticulum (tER). The transfer of membranes from the endoplasmic reticulum to the Golgi apparatus occurs via 50-70 nm transition vesicles which derive from part-rough, part-smooth transitional elements of the endoplasmic reticulum (tER). Vesicle budding from the tER is an ATP-dependent process. The ternary complex containing UFD1, VCP and

LOCALIZAÇÃO

Cytoplasm, cytosolEndoplasmic reticulumNucleusCytoplasm, Stress granule

VIAS BIOLÓGICAS (10)
AggrephagyAttachment and EntryAttachment and EntryAMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)ABC-family proteins mediated transport
MECANISMO DE DOENÇA

Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 1

An autosomal dominant disease characterized by disabling muscle weakness clinically resembling to limb girdle muscular dystrophy, osteolytic bone lesions consistent with Paget disease, and premature frontotemporal dementia. Clinical features show incomplete penetrance.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
229.2 TPM
Linfócitos
209.1 TPM
Músculo esquelético
193.2 TPM
Aorta
172.4 TPM
Útero
171.2 TPM
OUTRAS DOENÇAS (10)
frontotemporal dementia and/or amyotrophic lateral sclerosis 6inclusion body myopathy with Paget disease of bone and frontotemporal dementia type 1Charcot-Marie-Tooth disease type 2Yamyotrophic lateral sclerosis
HGNC:12666UniProt:P55072
UNC13AProtein unc-13 homolog AMajor susceptibility factor inAltamente restrito
FUNÇÃO

Plays a role in vesicle maturation during exocytosis as a target of the diacylglycerol second messenger pathway. Involved in neurotransmitter release by acting in synaptic vesicle priming prior to vesicle fusion and participates in the activity-dependent refilling of readily releasable vesicle pool (RRP). Essential for synaptic vesicle maturation in most excitatory/glutamatergic but not inhibitory/GABA-mediated synapses. Facilitates neuronal dense core vesicles fusion as well as controls the loc

LOCALIZAÇÃO

CytoplasmCell membranePresynaptic cell membranePresynaptic active zone

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
89.8 TPM
Cerebelo
86.6 TPM
Pituitária
69.4 TPM
Brain Frontal Cortex BA9
64.3 TPM
Córtex cerebral
52.0 TPM
OUTRAS DOENÇAS (1)
amyotrophic lateral sclerosis
HGNC:23150UniProt:Q9UPW8
FUSRNA-binding protein FUSDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

DNA/RNA-binding protein that plays a role in various cellular processes such as transcription regulation, RNA splicing, RNA transport, DNA repair and damage response (PubMed:27731383). Binds to ssRNA containing the consensus sequence 5'-AGGUAA-3' (PubMed:21256132). Binds to nascent pre-mRNAs and acts as a molecular mediator between RNA polymerase II and U1 small nuclear ribonucleoprotein thereby coupling transcription and splicing (PubMed:26124092). Also binds its own pre-mRNA and autoregulates

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
mRNA Splicing - Major PathwaymRNA PolyadenylationProcessing of Capped Intron-Containing Pre-mRNADengue Virus-Host Interactions
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
193.2 TPM
Cérebro - Hemisfério cerebelar
173.6 TPM
Cerebelo
159.0 TPM
Cervix Ectocervix
155.5 TPM
Cervix Endocervix
152.7 TPM
OUTRAS DOENÇAS (7)
tremor, hereditary essential, 4amyotrophic lateral sclerosis type 6myxoid/round cell liposarcomajuvenile amyotrophic lateral sclerosis
HGNC:4010UniProt:P35637

Medicamentos e terapias

TOFERSENPhase 4

Mecanismo: SOD1 mRNA antisense inhibitor

RILUZOLEPhase 4

Mecanismo: Sodium channel alpha subunit blocker

MECASERMINPhase 3

Mecanismo: Insulin-like growth factor I receptor agonist

QUINIDINEPhase 3

Mecanismo: Sodium channel alpha subunit blocker

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

291 variantes patogênicas registradas no ClinVar.

🧬 TREM2: NM_018965.4(TREM2):c.491T>A (p.Leu164Ter) ()
🧬 TREM2: NM_018965.4(TREM2):c.428del (p.Phe143fs) ()
🧬 TREM2: NM_018965.4(TREM2):c.41-1G>C ()
🧬 TREM2: NM_018965.4(TREM2):c.114T>G (p.Tyr38Ter) ()
🧬 TREM2: NM_018965.4(TREM2):c.257A>T (p.Asp86Val) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 8,784 variantes classificadas pelo ClinVar.

5270
3514
VUS (60.0%)
Benigna (40.0%)
VARIANTES MAIS SIGNIFICATIVAS
TBK1: NM_013254.4(TBK1):c.1310A>T (p.Glu437Val) [Uncertain significance]
TBK1: NM_013254.4(TBK1):c.1928A>T (p.Glu643Val) [Uncertain significance]
LOC126807526: NM_018834.6(MATR3):c.2123C>T (p.Ala708Val) [Uncertain significance]
TBK1: NM_013254.4(TBK1):c.433A>G (p.Ile145Val) [Uncertain significance]
MATR3: NM_018834.6(MATR3):c.242A>G (p.His81Arg) [Uncertain significance]

Vias biológicas (Reactome)

172 vias biológicas associadas aos genes desta condição.

Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell DAP12 interactions DAP12 signaling Other semaphorin interactions Retinoid metabolism and transport RAB GEFs exchange GTP for GDP on RABs RAC1 GTPase cycle FGFR2 alternative splicing Sphingolipid de novo biosynthesis Platelet degranulation Translocation of SLC2A4 (GLUT4) to the plasma membrane Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane Gap junction assembly MHC class II antigen presentation Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion Regulation of PLK1 Activity at G2/M Transition HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Prefoldin mediated transfer of substrate to CCT/TriC Formation of tubulin folding intermediates by CCT/TriC Post-chaperonin tubulin folding pathway Recycling pathway of L1 Hedgehog 'off' state Anchoring of the basal body to the plasma membrane Cargo trafficking to the periciliary membrane Intraflagellar transport RHO GTPases activate IQGAPs RHO GTPases Activate Formins COPI-mediated anterograde transport COPI-dependent Golgi-to-ER retrograde traffic COPI-independent Golgi-to-ER retrograde traffic Mitotic Prometaphase The role of GTSE1 in G2/M progression after G2 checkpoint AURKA Activation by TPX2 Carboxyterminal post-translational modifications of tubulin NOD1/2 Signaling Pathway TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway Ub-specific processing proteases Negative regulators of DDX58/IFIH1 signaling Potential therapeutics for SARS Neurodegenerative Diseases Transport of Mature mRNA derived from an Intron-Containing Transcript Signaling by ERBB2 Signaling by ERBB4 SHC1 events in ERBB2 signaling PI3K events in ERBB4 signaling SHC1 events in ERBB4 signaling Nuclear signaling by ERBB4 Downregulation of ERBB4 signaling PIP3 activates AKT signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling Estrogen-dependent gene expression Long-term potentiation Signaling by ERBB2 KD Mutants Signaling by ERBB2 TMD/JMD mutants Synthesis of PIPs at the Golgi membrane Synthesis of PIPs at the early endosome membrane Synthesis of PIPs at the late endosome membrane Neddylation Antigen processing: Ubiquitination & Proteasome degradation RHOA GTPase cycle RHOC GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOG GTPase cycle HIV Transcription Initiation RNA Polymerase II HIV Promoter Escape Transcription of the HIV genome HATs acetylate histones RNA Polymerase II Pre-transcription Events Regulation of TP53 Activity through Phosphorylation RNA Polymerase II Promoter Escape RNA Polymerase II Transcription Pre-Initiation And Promoter Opening RNA Polymerase II Transcription Initiation RNA Polymerase II Transcription Initiation And Promoter Clearance PINK1-PRKN Mediated Mitophagy TBC/RABGAPs TICAM1-dependent activation of IRF3/IRF7 Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation PPARA activates gene expression Transcriptional activation of mitochondrial biogenesis Activation of PPARGC1A (PGC-1alpha) by phosphorylation Transcriptional regulation of white adipocyte differentiation SUMOylation of transcription cofactors Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Heme signaling MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 Regulation of MITF-M dependent genes involved in metabolism Expression of BMAL (ARNTL), CLOCK, and NPAS2 RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression Mitochondrial protein import Cargo recognition for clathrin-mediated endocytosis Detoxification of Reactive Oxygen Species Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation IRF3 mediated activation of type 1 IFN DDX58/IFIH1-mediated induction of interferon-alpha/beta Regulation of innate immune responses to cytosolic DNA STAT6-mediated induction of chemokines IRF3-mediated induction of type I IFN Interleukin-37 signaling TRAF3-dependent IRF activation pathway TRAF6 mediated IRF7 activation SARS-CoV-1 activates/modulates innate immune responses SARS-CoV-2 activates/modulates innate and adaptive immune responses NRIF signals cell death from the nucleus p75NTR recruits signalling complexes NF-kB is activated and signals survival Interleukin-1 signaling Pexophagy Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Nuclear events mediated by NFE2L2 Phase I - Functionalization of compounds Neutrophil degranulation Adherens junctions interactions tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis Synthesis of 5-eicosatetraenoic acids Atorvastatin ADME XBP1(S) activates chaperone genes Regulation of pyruvate metabolism Signaling by ROBO receptors PCP/CE pathway mRNA Splicing - Major Pathway Processing of Capped Intron-Containing Pre-mRNA SARS-CoV-1-host interactions SARS-CoV-1 modulates host translation machinery mRNA Polyadenylation Dengue Virus-Host Interactions Budding and maturation of HIV virion Macroautophagy Pyroptosis Endosomal Sorting Complex Required For Transport (ESCRT) HCMV Late Events Late endosomal microautophagy Sealing of the nuclear envelope (NE) by ESCRT-III Translation of Replicase and Assembly of the Replication Transcription Complex Translation of Replicase and Assembly of the Replication Transcription Complex Translesion Synthesis by POLH HSF1 activation ABC-family proteins mediated transport N-glycan trimming in the ER and Calnexin/Calreticulin cycle Hedgehog ligand biogenesis Hh mutants are degraded by ERAD Defective CFTR causes cystic fibrosis Josephin domain DUBs Ovarian tumor domain proteases E3 ubiquitin ligases ubiquitinate target proteins Protein methylation RHOH GTPase cycle Aggrephagy Attachment and Entry Attachment and Entry Dengue Virus Genome Translation and Replication AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado2
3Fase 33
2Fase 25
·Pré-clínico14
Medicamentos catalogadosEnsaios clínicos· 4 medicamentos · 20 ensaios
✓ Aprovados — podem ser usados hoje
TOFERSENRILUZOLE
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Esclerose lateral amiotrófica

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

20 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07467187 · Invasive Home Ventilation in DenmarkRecrutando
NCT03225144 · Investigating Complex Neurodegenerative Disorders Related to…Recrutando
NCT07161999 · Study of COYA 302 for the Treatment of ALSRecrutando
PHASE2
NCT05747937 · Longitudinal Assessment of Autonomic and Sensory Nervous Sys…Recrutando
NA
NCT04297683 · HEALEY ALS Platform Trial - Master ProtocolRecrutando
PHASE2, PHASE3
NCT07357428 · Connect-One: Early Feasibility Study of Connexus® Brain-Comp…Recrutando
NA
NCT07017946 · Intestinal Microbiome Transplant in ALSRecrutando
PHASE1, PHASE2
NCT05204017 · Comprehensive Analysis Platform To Understand, Remedy and El…Recrutando
NCT06450691 · Modeling Amyotrophic Lateral Sclerosis With FibroblastsRecrutando
NA
NCT07287397 · Study is to Assess the Safety and Tolerability of VTx-002 in…Recrutando
PHASE1, PHASE2
NCT07521930 · Interfacing With NeuroTechnology to Expand Neural Throughput…Recrutando
NA
NCT07259980 · A Study to Learn More About the Long-Term Safety of Tofersen…Recrutando
NCT06819124 · Examining Interactions Between PALS and CaregiversRecrutando
NA
NCT03174938 · The Swedish BioFINDER 2 StudyRecrutando
NA
NCT07509125 · Ultra-High Resolution PET in Aging, Neurodegeneration and Ps…Recrutando
NA
NCT07142291 · PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to M…Recrutando
PHASE2
NCT07502677 · Diagnostic Accuracy of SleepImage Technology for Detecting R…Recrutando
NCT05407324 · Dazucorilant in Patients With Amyotrophic Lateral SclerosisRecrutando
PHASE2
NCT06856850 · Disease Biosignatures in ALS/FTD Spectrum: New Impactful Bio…Recrutando
NCT07491484 · Impact of Physical Functioning on Patient-Reported Outcomes …Recrutando

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
21.066 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 21.066

#1

Muscle MRI and Muscle Ultrasound Applications in MND/ALS: Academic Insights and Clinical Opportunities.

European journal of neurology2026 Mar

Este artigo destaca que, embora a deficiência na ELA seja primariamente muscular, a imagem dos músculos tem sido uma área negligenciada como biomarcador para a doença. No entanto, uma revisão sistemática demonstrou que técnicas não-invasivas como ressonância magnética e ultrassom são eficazes na detecção da degeneração muscular característica da ELA, avaliando desde volume e conteúdo de gordura até fasciculações. Essa é uma oportunidade valiosa para médicos e pacientes, pois esses métodos, de fácil implementação, podem aprimorar o diagnóstico, monitorar a progressão e avaliar a resposta a tratamentos para a ELA.

🇧🇷 traduzido
#2

Sleep Disorders in Neurodegenerative Diseases: Pathological Correlations and Underlying Mechanisms.

Neuroscience bulletin2026 Mar 22

Para pacientes e médicos, é crucial saber que: Pacientes com Esclerose Lateral Amiotrófica (ELA), assim como em outras doenças neurodegenerativas, frequentemente sofrem de distúrbios do sono significativos. Contudo, esses distúrbios não são apenas uma consequência da ELA, mas também podem exacerbar sua progressão, numa relação bidirecional complexa. Consequentemente, o tratamento eficaz desses distúrbios do sono é crucial, pois pode proporcionar alívio sintomático e até mesmo ter efeitos modificadores na doença.

🇧🇷 traduzido
#3

Embedded CRISPRi Enhances Gene-Silencing Efficiency in Drosophila.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)2026 Mar 20

Cientistas desenvolveram um novo método, chamado emCRISPRi, que aprimora drasticamente a capacidade de "desligar" genes específicos, uma ferramenta crucial para entender e combater doenças. Esta nova abordagem mostrou-se particularmente eficaz na redução da toxicidade causada pela proteína TDP-43, um fator chave na Esclerose Lateral Amiotrófica (ELA), em um modelo de laboratório. Essas descobertas representam um avanço promissor no estudo da ELA, com potencial significativo para o desenvolvimento futuro de novas terapias e uma melhor compreensão da doença.

🇧🇷 traduzido
#4

Subcortical microstructural impairment in amyotrophic lateral sclerosis: clinical correlates of neurite orientation dispersion and density imaging (NODDI) changes.

Frontiers in neuroscience2026

Este estudo investigou a microestrutura de regiões cerebrais profundas em pacientes com Esclerose Lateral Amiotrófica (ELA) usando uma técnica avançada de ressonância magnética (NODDI). Não foram encontradas diferenças microestruturais robustas entre pacientes e controles, e as associações observadas entre a microestrutura dessas áreas e os sintomas da ELA (respiratórios, motores) foram apenas preliminares e não estatisticamente confirmadas. Isso sugere a necessidade de mais pesquisas em grupos maiores para entender melhor o papel dessas regiões na doença.

🇧🇷 traduzido
#5

Small heat shock proteins HspB1 and HspB5 differentially alter the condensation and aggregation of the TDP-43 low-complexity domain.

Protein science : a publication of the Protein Society2026 Apr

Em doenças neurodegenerativas como a Esclerose Lateral Amiotrófica (ELA), a proteína TDP-43 se condensa e agrega de forma prejudicial. Este estudo demonstrou que as proteínas HspB1 e HspB5 atuam como "chaperones", regulando a condensação da TDP-43 e prevenindo sua agregação tóxica, embora com mecanismos ligeiramente diferentes. Esses achados são de grande relevância, pois identificam HspB1 e HspB5 como potenciais alvos terapêuticos para o desenvolvimento de tratamentos que possam mitigar a formação de agregados tóxicos de TDP-43 em pacientes.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

📚 EuropePMC17.515 artigos no totalmostrando 198

2026

Muscle MRI and Muscle Ultrasound Applications in MND/ALS: Academic Insights and Clinical Opportunities.

European journal of neurology
2026

A phase I study to evaluate the dosimetry and safety of [89Zr]Zr-DFO-AP-101, a new antibody-based radiopharmaceutical to detect misfolded SOD1 in amyotrophic lateral sclerosis.

European journal of nuclear medicine and molecular imaging
2026

Clinical and Sociodemographic Profile of Familial Amyotrophic Lateral Sclerosis Type 8 Compared to the Sporadic Form.

Arquivos de neuro-psiquiatria
2026

Role of Pentacyclic Triterpenes in the Management of Neurological Disorders: An Insight into Molecular Mechanisms and Therapeutic Approaches.

Molecular neurobiology
2026

A Qualitive Investigation of Geographic Disparities in Genetic Testing and Care Access for Amyotrophic Lateral Sclerosis: Insights From Patient Journey Mapping.

Patient preference and adherence
2026

Predicting Disease Progression and Survival in Amyotrophic Lateral Sclerosis.

Muscle &amp; nerve
2026

Sleep Disorders in Neurodegenerative Diseases: Pathological Correlations and Underlying Mechanisms.

Neuroscience bulletin
2026

Uncoupling of apnea-hypopnea index and oxygen desaturation in als: characterization and diagnostic implications of an "AHI-SpO₂ dissociation" phenotype.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

The p75NTR Signaling Axis: Bridging Neurodevelopmental Homeostasis, Pathological Mechanisms, and Therapeutic Strategies in Neurodegenerative Diseases.

Ageing research reviews
2026

Associations between pre-disease biomarkers of persistent organic pollutants and amyotrophic lateral sclerosis risk in four European cohorts.

Environmental research
2026

Decoding Neuroinflammatory Pathways: The Role of the CXCL12-CXCR4/CXCR7 Axis in ALS-Related Cognitive Impairment.

Molecular neurobiology
2026

Targeting Autophagy with Bioactive Compounds: Therapeutic Potential in Neurodegenerative Disorders.

Current neuropharmacology
2026

ALS mutations disrupt self-association between the ubiquilin STI1 hydrophobic groove and internal placeholder sequences.

The EMBO journal
2026

Embedded CRISPRi Enhances Gene-Silencing Efficiency in Drosophila.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2026

[Protective effect of a CREB3 gain-offunction variant in amyotrophic lateral sclerosis].

Medecine sciences : M/S
2026

Subcortical microstructural impairment in amyotrophic lateral sclerosis: clinical correlates of neurite orientation dispersion and density imaging (NODDI) changes.

Frontiers in neuroscience
2026

Registered Dietitians' perspectives on nutrition management of persons living with amyotrophic lateral sclerosis.

Neurodegenerative disease management
2026

Plasma proteomic trajectories before the onset of neurodegenerative diseases.

Neurodegenerative disease management
2026

Repeat expansion RNA elicits toxicity through hybrid G-quadruplexes with promoter DNA.

Neuron
2026

Small heat shock proteins HspB1 and HspB5 differentially alter the condensation and aggregation of the TDP-43 low-complexity domain.

Protein science : a publication of the Protein Society
2026

Identifying priorities for a national motor neurone disease (amyotrophic lateral sclerosis) guideline: results from an Australian online survey.

Disability and rehabilitation
2026

Herpesvirus genome integration in whole-genome sequences of dementia and control cohorts.

Alzheimer's &amp; dementia : the journal of the Alzheimer's Association
2026

Systemic dysregulation of apolipoproteins in amyotrophic lateral sclerosis serum.

FEBS open bio
2026

High Prevalence of SOD1 Pathogenic Variants in the UK Biobank: Implications for Early Intervention in Amyotrophic Lateral Sclerosis.

Annals of neurology
2026

Author Correction: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis.

Nature
2026

Paraspeckle condensation is controlled via TDP-43 polymerization and linked to neuroprotection.

Nature cell biology
2026

Implanted brain-computer interface functionality during nighttime in late-stage amyotrophic lateral sclerosis.

Scientific reports
2026

Reduced nuclear TDP-43 and cytoplasmic DLK1 as markers of motor neuron degeneration in amyotrophic lateral sclerosis.

Journal of neuropathology and experimental neurology
2026

Identification of tofersen PD-response biomarkers in VALOR clinical trial CSF via multiplexed quantitative proteomics.

Cell reports. Medicine
2026

Employing an integrated computational simulation strategy to identify high-affinity ligands for TDP-43 amyloid proteins.

Bioorganic &amp; medicinal chemistry
2026

From observation to optimization: behavioral metrics that matter in KPI based home cage monitoring.

Frontiers in behavioral neuroscience
2026

Sarcopenia in amyotrophic lateral sclerosis: a key predictor of respiratory dysfunction and disease progression.

Frontiers in nutrition
2026

From Refractory Epilepsy to Neurodegeneration: Emerging Mechanistic and Clinical Insights Into the Ketogenic Diet.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2026

The role of IRF5 in Microglia-Mediated neuroinflammation in ALS.

Neuroscience letters
2026

The role of TDP-43 fragments in regular cellular functions and homeostatic failure.

Neurobiology of disease
2026

ALS motor phenotypes: a revised 'OPM' classification.

Amyotrophic lateral sclerosis &amp; frontotemporal degeneration
2026

Sexual health in neuromuscular diseases: Neglected challenges revealed by a scoping review.

Journal of neuromuscular diseases
2026

Valosin-containing protein counteracts ATP-driven dissolution of FUS condensates through its ATPase activity in vitro.

FEBS letters
2026

Restoring rapid natural bimanual typing with a neuroprosthesis after paralysis.

Nature neuroscience
2026

High-throughput screening of ALS patient iPSC-derived spinal motor neurons identifies novel compounds that increase neurofilament light chain expression.

SLAS discovery : advancing life sciences R &amp; D
2026

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice.

Journal of visualized experiments : JoVE
2026

Comparing vowel intelligibility across interactive and non-interactive tasks in disordered speech.

JASA express letters
2026

Local Translation in Glial Cells of the Brain.

Annual review of cell and developmental biology
2026

TDP-43 impairs glycolysis by sequestering hexokinase 1 in amyotrophic lateral sclerosis.

Acta neuropathologica
2026

Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical Trial.

JAMA neurology
2025

Ubiquitin signatures on aggregating proteins in neurodegeneration.

Essays in biochemistry
2026

Decoding neurodegeneration one cell at a time.

The Journal of clinical investigation
2026

Splicing the narrative: alternative TARDBP splicing and its relation to neurodegeneration in ALS and FTD.

The Journal of clinical investigation
2026

Consequences of the Novel ALS-Associated KIF5A Variant c.2993-6C > A for Exon 27 Splicing and Axonal Transport of SFPQ.

Neurology. Genetics
2026

Approaching Serious Illness Conversations in Amyotrophic Lateral Sclerosis Using Telehealth: A Practical Guide.

Neurology. Clinical practice
2026

Functional validation of the novel KIF5A p.R17Q VUS reveals defective axonal transport in iPSC-motoneurons from a SPG10 patient.

Frontiers in genetics
2026

Autophagy-exosome crosstalk in neurodegeneration: Mechanisms and therapeutic opportunities.

Pharmacology &amp; therapeutics
2026

The role of zinc transporter 1 (ZnT1) in health and disease: From molecular mechanisms to therapeutic opportunities.

European journal of medicinal chemistry
2026

Analysis of immune-related alterations in blood and spinal cord of canine degenerative myelopathy, a spontaneous model of amyotrophic lateral sclerosis.

Scientific reports
2026

Human FUS is toxic via association with RNA polymerase II in Drosophila.

Cell death &amp; disease
2026

Aldh3a1-mediated detoxification of reactive aldehydes contributes to distinct muscle responses to amyotrophic lateral sclerosis progression.

Free radical biology &amp; medicine
2026

Translating neurofilament light chain testing into clinical practice: a multidisciplinary implementation roadmap.

Clinical chemistry and laboratory medicine
2026

From Environment to Symptoms: Mapping Premorbid Risk Factors onto Clinical Features of ALS in a Patient-Reported Database in China.

Neurology and therapy
2026

PatientFlow: Learning to generate mixed-type longitudinal clinical data with flow matching.

Artificial intelligence in medicine
2026

Propensity Score-Based Stratified Win Ratio for Augmented Control Designs.

Statistics in medicine
2026

HML-2 env knockdown by AAV9-mediated miRNAs attenuates amyotrophic lateral sclerosis-like manifestations in mice.

Brain : a journal of neurology
2026

Quantification of Tongue Motor Dysfunction in Amyotrophic Lateral Sclerosis Using a Smartphone-Based Task and Deep Learning.

Sensors (Basel, Switzerland)
2026

Motor Neuron Disease with Guillain-Barré Syndrome? Motor Band Sign with Anti-GQ1b Antibodies.

Diagnostics (Basel, Switzerland)
2026

TBK1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: Mechanistic Insights into Impaired Autophagy and Proteostatic Failure.

Cells
2026

TIA1 Mutant Mouse Model Exhibits Motor Deficits and Neurodegenerative Characteristics of Amyotrophic Lateral Sclerosis.

Cells
2026

The evolution of speech communication devices for anarthria: a review.

Journal of neurology
2026

Assessing green space exposure: From traditional metrics to the Green Exposure Index (GEI) with application to a Northern Italy residential dataset.

Environmental research
2026

The role of MyD88 in the nervous system: Neuronal functions, implications in neurological diseases, and therapeutic potential.

Pharmacology &amp; therapeutics
2026

Reversibility and β-sheet formation are decoupled in tau condensate aging.

Proceedings of the National Academy of Sciences of the United States of America
2026

Ferritin in ferroptosis: Implications for neurodegenerative diseases (Review).

International journal of molecular medicine
2026

Immunotherapies for risk reduction in age-associated neurodegenerative diseases: impact of sex and treatment duration.

medRxiv : the preprint server for health sciences
2026

An Unsuspected Intraneural Perineurioma in a Pediatric Patient: A Case Report.

Cureus
2026

Plasma isomiRs as Candidate Biomarkers for Amyotrophic Lateral Sclerosis.

Neurology. Genetics
2026

Tofersen treatment in SOD1 p.Leu145Phe ALS: real-world outcomes in a genetically homogeneous Croatian cohort.

Amyotrophic lateral sclerosis &amp; frontotemporal degeneration
2026

Serum Trace Elements and Their Associations with Disease Progression and Survival in Sporadic Amyotrophic Lateral Sclerosis: Insights from a Chinese Cohort.

Biomedical and environmental sciences : BES
2026

Immune imbalance between T helper 1, T helper 17 and regulatory T cells fuels amyotrophic lateral sclerosis pathogenesis: disease trajectory, diagnosis and therapeutic implications.

Journal of neuroinflammation
2026

An Unusual Presentation of Juvenile Amyotrophic Lateral Sclerosis with Superoxide Dismutase 1 Mutation: Subacute Bulbar Palsy With Asymmetric Limb Weakness.

Annals of Indian Academy of Neurology
2026

Motoneurons inhibitory synapses homeostatically respond to neuronal activity and modulate Amyotrophic Lateral Sclerosis pathogenesis.

The Journal of neuroscience : the official journal of the Society for Neuroscience
2026

Respiratory alterations in patients with amyotrophic lateral sclerosis.

Medicina clinica
2026

Targeting PGAM5-driven mitochondrial integrated stress response slows ALS progression across subtypes.

Neuron
2026

Effect of G4C2repeat expansions on the motion of lysosomes inside neurites.

Physical biology
2026

Advancement in therapeutic application of quantum dots in amyotrophic lateral sclerosis: current opportunities and challenges.

Drug delivery and translational research
2026

Non-invasive ventilation support during feeding tube placement in amyotrophic lateral sclerosis patients with moderate to severe ventilatory impairment: an update.

Panminerva medica
2026

Oral Health in Amyotrophic Lateral Sclerosis: Feasibility of Oral Screening and Determinants of Poor Outcomes.

Muscle &amp; nerve
2026

Oral Health Care Services, Barriers and Enablers to Maintaining Good Oral Health in Motor Neurone Disease: A Scoping Review.

Community dentistry and oral epidemiology
2026

Identification of drug repurposing candidates for amyotrophic lateral sclerosis using electronic health records: a retrospective cohort study.

The Lancet. Digital health
2026

ALS and Huntington Disease: Unraveling the Connections between TDP-43 and Huntingtin.

The Journal of neuroscience : the official journal of the Society for Neuroscience
2026

Spinal motoneuron excitability is homeostatically regulated through β-adrenergic neuromodulation in wild-type and presymptomatic SOD1 mice.

Progress in neurobiology
2026

PAICS mediates DNA damage and cerebellar neuronal loss in C9orf72 amyotrophic lateral sclerosis.

Brain : a journal of neurology
2026

Innovation, Adaptation, and Human Dignity in Assistive Robotics in Amyotrophic Lateral Sclerosis: A Rehabilitation Medicine Perspective.

Journal of biotechnology and biomedicine
2026

Mesenchymal stem cells and the central nervous system: historical perspectives and future directions.

Frontiers in molecular neuroscience
2026

cGAS inhibition delays TDP-43-driven ALS Pathogenesis.

bioRxiv : the preprint server for biology
2026

Distinct Prescription Patterns Emerge Years Before ALS Diagnosis: A Nationwide Registry-Based Study.

Annals of neurology
2026

Fructose-2,6-bisphosphate restores TDP-43 pathology-driven genome repair deficiency in motor neuron diseases.

Communications biology
2026

TDP-43 pathology triggers neuroinflammation and cognitive impairment by inducing microglial necroptosis.

EMBO molecular medicine
2026

Long-wave infrared imaging for respiratory rate measurement in a patient with amyotrophic lateral sclerosis: A case report.

The Journal of international medical research
2026

Ubiquitin-specific peptidase-19 links TDP-43 aggregation to ER stress.

Proceedings of the National Academy of Sciences of the United States of America
2026

How to measure person-centred care in people living with ALS: development and validation of the patient experience PEMALS questionnaire.

Amyotrophic lateral sclerosis &amp; frontotemporal degeneration
2026

Cofilin hyperphosphorylation triggers TDP-43 pathology in sporadic amyotrophic lateral sclerosis.

Brain : a journal of neurology
2026

Pml loss worsens NEK1-linked ALS and Pml induction drives NEK1 degradation, precluding disease onset.

The FEBS journal
2026

[Immune Cells and Proteins Associated with Disease Progression in Amyotrophic Lateral Sclerosis: New Insights from Multiomics Analyses].

Brain and nerve = Shinkei kenkyu no shinpo
2026

Motor neuron disease can present as a paraneoplastic neurologic syndrome with various phenotypes.

Brain communications
2026

Exercise pressor reflex in Amyotrophic lateral sclerosis patients.

Scientific reports
2026

Multi-modal dissection of cell-type specific TDP-43 pathology in the motor cortex.

Nature communications
2026

"A rough and swirling sea": Voicing Amyotrophic Lateral Sclerosis through discourse analysis.

Journal of health psychology
2026

Clinical Validation of Plasma p-217tau in Neurological Diseases.

Annals of clinical and translational neurology
2026

Kenny is the adaptor protein for ubiquitin-dependent mitophagy in Drosophila melanogaster.

Autophagy reports
2026

An electrochemical enzyme-linked immunosorbent assay for interleukin 18 quantification in 3D skin models derived from ALS patients.

Biosensors &amp; bioelectronics
2026

RNA-Binding Proteins TDP-43 and FUS Promote R-Loop Resolution and Regulate Transcription Termination.

The Journal of biological chemistry
2026

Unraveling amyotrophic lateral sclerosis: a novel peripherin mutation in a young male with sporadic onset.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

ALS untangled #83: clenbuterol.

Amyotrophic lateral sclerosis &amp; frontotemporal degeneration
2026

Brain Folding Trajectories in Amyotrophic Lateral Sclerosis.

Human brain mapping
2026

Decoding the functions of nuclear speckles in neurodegeneration.

Trends in neurosciences
2026

Integrating Serum Neurofilament Light Chain Into Amyotrophic Lateral Sclerosis Diagnostic Criteria.

Muscle &amp; nerve
2026

Cell-free miRNAs are pharmacodynamic biomarkers for enhanced DICER activity by enoxacin in human patients with ALS.

Molecular therapy : the journal of the American Society of Gene Therapy
2026

Expanding the Motor Band Sign in Motor Neuron Disease Using 7T MRI: Visualization of Cortical Layer-Dependent Iron Deposition in the Primary Motor Cortex.

Muscle &amp; nerve
2026

Impairment of brain short association fibers across clinical stages in amyotrophic lateral sclerosis: a new biomarker mirroring disease progression.

BMC medicine
2026

Calprotectin as an immune-dysregulation biomarker in amyotrophic lateral sclerosis: Insights for diagnosis and therapy.

Revue neurologique
2026

Pathogenic VCP (p.Arg453Trp) variant in three siblings with frontotemporal dementia-amyotrophic lateral sclerosis spectrum: A Turkish family.

Clinical neurology and neurosurgery
2026

Unveiling the entropic role of hydration water in SOD1 partitioning within FUS condensate.

The Journal of chemical physics
2026

"What about me? I'm supposed to be … superhuman?": exploring staff perspectives on how to deliver high quality psychological care for people living with amyotrophic lateral sclerosis.

Neurodegenerative disease management
2026

3D Artificial Skin Model As a Novel Strategy for the Detection of Pyroptosis-Cascade Activation in Amyotrophic Lateral Sclerosis.

ACS applied materials &amp; interfaces
2026

Brain organoids as precision models for neurodegenerative diseases: from disease modeling to drug discovery.

Frontiers in neuroscience
2026

Hypothesis-free evaluation of circulating metabolome provides cell-specific insights regarding the role of energy substrate availability in amyotrophic lateral sclerosis.

BMC medicine
2026

Subjective sleep quality in amyotrophic lateral sclerosis: a systematic review and meta-analysis.

Amyotrophic lateral sclerosis &amp; frontotemporal degeneration
2026

Bridging the gap: understanding participation barriers in ALS clinical trials through on-the-ground insights.

Amyotrophic lateral sclerosis &amp; frontotemporal degeneration
2026

Gadolinium enhancement of the cauda equina in a case of familial ALS with p.S135G SOD1 mutation.

Amyotrophic lateral sclerosis &amp; frontotemporal degeneration
2026

Exploring the use of narrative-based approaches in individuals with amyotrophic lateral sclerosis: A narrative review.

Palliative &amp; supportive care
2026

Copper Homeostasis and Cuproptosis in Neurological Disorders.

Drug design, development and therapy
2025

Glioinflammation: disease-associated microglia and astrocytes in psychiatric disorders, neurodegeneration, and senescence.

Frontiers in cellular neuroscience
2026

Brain Organoids as Emerging Platforms for Modeling Neurodegenerative Diseases: Progress, Challenges, and Future Directions.

Journal of neurochemistry
2026

Comparison of AAV9-driven motor neuron transduction following different CNS-directed delivery methods in mice.

Scientific reports
2026

Decreased metallothionein-3 expression in the human spinal cord is a common feature of amyotrophic lateral sclerosis and multiple sclerosis.

Scientific reports
2026

TDP-43 phosphorylation: Exploring kinases, phosphatases, and therapeutic potential in neurodegeneration.

Journal of Alzheimer's disease : JAD
2026

Mesenchymal stem cell therapies for neurodegenerative diseases: Advancements, challenges, and opportunities.

Neural regeneration research
2026

Unlocking amyotrophic lateral sclerosis diagnosis: How artificial intelligence is transforming early prediction.

Neural regeneration research
2026

ALSUntangled #82: N-acetylcysteine.

Amyotrophic lateral sclerosis &amp; frontotemporal degeneration
2026

Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival.

Brain pathology (Zurich, Switzerland)
2026

Disruption of the angiopoietin-like system connects lipid homeostasis and hypothalamic dysfunction in ALS.

BMC medicine
2026

Intranasal administration of human mesenchymal stromal cell-derived small extracellular vesicles delays disease progression in the SOD1(G93A) mouse model.

Molecular brain
2026

Exploring the Lived Experiences of Individuals with Amyotrophic Lateral Sclerosis (ALS): A Qualitative Study and Conceptual Model of Signs, Symptoms, and Functional Impacts.

Neurology and therapy
2026

From scaffold to effector: reframing GFAP in neurodegeneration.

Journal of advanced research
2026

A tri-responsive sensor based on co-encapsulated organic probes and multifunctional bimetallic V/Ce-MOF nanozyme in a hydrogel for the detection of l-Serine in saliva.

Talanta
2026

FUS is an N1- and N6-methyladenosine-binding protein.

Nucleic acids research
2026

Loss of Splicing Homeostasis as a Hallmark of Aging.

Molecular and cellular biology
2026

Granules Gone Rogue: Nuclear and Cytoplasmic Ribonucleoprotein Structures in Amyotrophic Lateral Sclerosis-Fused in Sarcoma (ALS-FUS) Pathology.

Molecular neurobiology
2026

NeuroViOme: a viral orfeome collection for studies of neurodegenerative disease.

Journal of neurovirology
2026

The Amyotrophic Lateral Sclerosis House Call Program: A Single-Center Experience in the United States.

Neurology research international
2026

Moral decision-making in patients with neurodegenerative diseases: a systematic review.

Frontiers in psychology
2026

Heat shock proteins (Hsp70 and Hsp90) in neurodegeneration: pathogenic roles and therapeutic potential.

Frontiers in aging neuroscience
2026

Amyotrophic Lateral Sclerosis Caused by a Pathogenic Variant in SOD1 Gene: An Atypical Rapidly Progressive Phenotype.

Journal of clinical neuromuscular disease
2026

Respiratory Onset Amyotrophic Lateral Sclerosis in a Patient With C9orf72 Expansion.

Journal of clinical neuromuscular disease
2026

Exploring Intimacy in Amyotrophic Lateral Sclerosis: A Pilot Study of Educational Support in a Multidisciplinary Clinic.

Journal of clinical neuromuscular disease
2026

Voxel-mirrored homotopic connectivity in upper motor neuron-dominant amyotrophic lateral sclerosis is associated with different spread directions.

Brain imaging and behavior
2026

[Mechanism of action and clinical trial results of a new drug for amyotrophic lateral sclerosis (ALS), Mecobalamin (Rozebalamin®) for intramuscular injection, 25 mg].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica
2026

Voltage-gating and neuronal signalling in neurodegeneration: From neuropathology to therapeutic opportunities in motor neuron disease.

Neurobiology of disease
2026

Neuroinflammation and Oxidative Stress in SOD1 Animal Models of ALS: A Meta-analysis Study of Their Effects on Disease Onset and Progression.

Molecular neurobiology
2026

Modeling the growth of cytosolic TDP-43 inclusion bodies and accumulated neurotoxicity of misfolded oligomers in neurons.

Computer methods in biomechanics and biomedical engineering
2026

Small extracellular vesicles as emerging biomarkers and therapeutic targets in neurodegenerative diseases.

Clinica chimica acta; international journal of clinical chemistry
2026

Ginsenoside compound K inhibited the gelation of GGGGCC repeats and regulated co-aggregation with arginine-rich poly-dipeptides in C9orf72-related ALS.

International journal of biological macromolecules
2026

Constitutive neuronal expression and disease-associated upregulation of chitinases in amyotrophic lateral sclerosis.

Brain : a journal of neurology
2026

Patient and caregiver attitudes to cognitive and behavioral testing in Amyotrophic Lateral Sclerosis.

Neurodegenerative disease management
2026

Advances and Challenges in the Use of Spinal Cord Organoids in ALS.

Journal of integrative neuroscience
2026

Preferences for Healthcare Delivery in Amyotrophic Lateral Sclerosis (ALS): A Survey of Patients and Caregivers in the United States.

The patient
2026

KIF5A and ALS: a clinical and genetic description of a case series and review of literature.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Safety and biodistribution of intrathecal administration of mesenchymal stem cells (MSCs) and neurotrophin-releasing nanoparticles in a porcine CSF-guided delivery model for amyotrophic lateral sclerosis (ALS) drug discovery.

Scientific reports
2026

C9orf72-ALS mutation drives basal mitophagy impairments in iNeurons.

Frontiers in cellular neuroscience
2026

Human CSF proteogenomics links genetic variation to neurodegenerative disease proteins.

medRxiv : the preprint server for health sciences
2026

Neuronal Cell-Cycle Re-entry Defines Divergent Outcomes Through Replication-Dependent DNA Damage in ALS.

bioRxiv : the preprint server for biology
2026

Autophagy induction mitigates FUS aggregate formation and early synaptic dysfunction at the NMJ in the FUS-ALS model.

bioRxiv : the preprint server for biology
2026

Reversing Mitochondrial Dysfunction in Optineurin E50K Glaucoma: A Metabolic Approach to Neuroprotection.

Research square
2026

Antidepressant-Like Effects of n-Butylidenephthalide Using In Vivo and In Silico Approaches.

Pharmaceuticals (Basel, Switzerland)
2026

Impact of Built-In Software Monitoring on Survival in Amyotrophic Lateral Sclerosis Patients Receiving Home Mechanical Ventilation: A Cohort Study.

Journal of clinical medicine
2026

Amyotrophic Lateral Sclerosis (ALS) Genetics and Microbiota: A Comprehensive Review.

International journal of molecular sciences
2026

Antisense Dipeptide Repeat Proteins Drive Widescale Purine Metabolism Aberration in C9orf72 Amyotrophic Lateral Sclerosis via ADA.

International journal of molecular sciences
2026

PPAR-Delta Agonist Therapies Did Not Rescue Hallmark Disease Phenotypes in Two Sets of Preclinical Trials in ALS TDP-43 and C9orf72 Model Mice.

International journal of molecular sciences
2026

Amyotrophic Lateral Sclerosis: The State of the Art on Treatments and the Therapeutic Role of the Intestinal Microbiome in Human Studies.

International journal of molecular sciences
2026

Mesenchymal Stem Cell-Based Therapies Applied in Neurological Diseases: A Systematic Review.

Biomedicines
2026

An Artificial Intelligence-Driven Multimorbidity Framework Reveals a Shared Metabolic and Immune Core Across Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.

Biomedicines
2026

Absence of Neuromuscular Dysfunction in Mice with Gut Epithelium-Restricted Expression of ALS Mutation hSOD1G93A.

Biomolecules
2026

Exploring the ALS Multistep Model.

Brain sciences
2026

'Molecular and Cellular Neuroscience': Impacts of Eight Highly Cited Articles Published in This Section of Brain Sciences in 2024.

Brain sciences
2026

Enlarged Perivascular Spaces (EPVS) and the Risk of Amyotrophic Lateral Sclerosis (ALS): Evidence for Overlapping Genetic Signals in White Matter Without Causal Links.

Brain sciences
2026

Nomogram prediction model for prognosis of patients with amyotrophic lateral sclerosis.

BMC neurology
2026

Corrigendum to "Chronic exposure to l-BMAA cyanotoxin induces cytoplasmic TDP-43 accumulation and glial activation, reproducing an amyotrophic lateral sclerosis-like phenotype in mice" [Biomed. Pharmacother. 167 (2023) 115503].

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2026

Maximal motor unit firing rates decline with amyotrophic lateral sclerosis progression.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
2026

Safety profile of tofersen in amyotrophic lateral sclerosis: a systematic review and meta-analysis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Role of mitochondria in neuronal function and survival in the enteric and central nervous systems.

Cellular and molecular life sciences : CMLS
2026

Blood Lactate as a Prognostic Biomarker for Survival and Weight Loss in Amyotrophic Lateral Sclerosis: An Exploratory-Validation Study.

Annals of neurology
2026

Prevalence and Risk Factors of Dysphagia in Amyotrophic Lateral Sclerosis: A Retrospective Study Using the Nationwide Inpatient Sample Database.

Muscle &amp; nerve
2026

Visualization analysis of the use of traditional Chinese medicine in the diagnosis and treatment of rare diseases in mainland China based on CiteSpace.

Intractable &amp; rare diseases research
2026

Current status and future prospects of brain-computer interfaces in the field of neurological disease rehabilitation.

Frontiers in rehabilitation sciences
2026

Development and pilot testing of U1 Adaptor therapy targeting SOD1 expression for dogs with degenerative myelopathy.

Journal of veterinary internal medicine
2026

Fast and slow strains of misfolded mutant superoxide dismutase 1 in familial amyotrophic lateral sclerosis.

Acta neuropathologica communications
2026

Target-stabilized base editors enable robust high-fidelity RNA editing.

Nature communications
2026

The role of dentists in the recognition of neurodegenerative and systemic conditions with neurological involvement.

Oral surgery, oral medicine, oral pathology and oral radiology
2026

Profiling mitochondrial DNA indices across whole blood, plasma, and CSF in amyotrophic lateral sclerosis.

Journal of the neurological sciences
2026

Neuronal TDP-43 regulates myelin formation via neurexin 1 mRNA stabilization.

Proceedings of the National Academy of Sciences of the United States of America
Ver todos os 17.515 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Associação brasileira dedicada a Esclerose lateral amiotrófica (ELA).

Associação brasileira dedicada a Esclerose lateral amiotrófica (ELA).

Associação brasileira dedicada a Esclerose lateral amiotrófica (ELA).

Associação brasileira dedicada a Esclerose lateral amiotrófica (ELA).

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Esclerose lateral amiotrófica

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Muscle MRI and Muscle Ultrasound Applications in MND/ALS: Academic Insights and Clinical Opportunities.
    European journal of neurology· 2026· PMID 41872984mais citado
  2. Sleep Disorders in Neurodegenerative Diseases: Pathological Correlations and Underlying Mechanisms.
    Neuroscience bulletin· 2026· PMID 41866449mais citado
  3. Embedded CRISPRi Enhances Gene-Silencing Efficiency in Drosophila.
    Advanced science (Weinheim, Baden-Wurttemberg, Germany)· 2026· PMID 41861112mais citado
  4. Subcortical microstructural impairment in amyotrophic lateral sclerosis: clinical correlates of neurite orientation dispersion and density imaging (NODDI) changes.
    Frontiers in neuroscience· 2026· PMID 41859232mais citado
  5. Small heat shock proteins HspB1 and HspB5 differentially alter the condensation and aggregation of the TDP-43 low-complexity domain.
    Protein science : a publication of the Protein Society· 2026· PMID 41854301mais citado
  6. CAR Treg therapies for neurodegenerative diseases.
    iScience· 2026· PMID 41994333recente
  7. The effect of statins on the survival of patients with amyotrophic lateral sclerosis: a meta-analysis.
    Front Neurol· 2026· PMID 41993642recente
  8. Nuclear export modulates TDP-43 phase transitions and cytoplasmic aggregation.
    bioRxiv· 2026· PMID 41993496recente
  9. A region-delineated snRNA-seq atlas of mouse spinal cord across lifespan resolves the interaction of normative aging programs with SOD1-G93A ALS.
    bioRxiv· 2026· PMID 41993486recente
  10. Microprotein Regulates G-quadruplex Driven RNA Aggregation.
    bioRxiv· 2026· PMID 41993388recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:803(Orphanet)
  2. MONDO:0004976(MONDO)
  3. Esclerose Lateral Amiotrofica(PCDT · Ministério da Saúde)
  4. GARD:5786(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q206901(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Esclerose lateral amiotrófica
Compêndio · Raras BR

Esclerose lateral amiotrófica

ORPHA:803 · MONDO:0004976
🇧🇷 Brasil SUS
CEAF
1ARiluzolEdaravona
Geral
Prevalência
1-9 / 100 000
Herança
Autosomal dominant, Autosomal recessive, Not applicable
CID-10
G12.2 · Doença do neurônio motor
CID-11
Ensaios
38 ativos
Medicamentos
4 registrados
Início
Adult
Prevalência
5.2 (Europe)
MedGen
UMLS
C0002736
Repurposing
2 candidatos
eperisoneacetylcholine receptor antagonist
riluzoleglutamate inhibitor
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades